Company Quick10K Filing
Vaparia
10-Q 2020-03-31 Filed 2020-05-15
10-K 2019-12-31 Filed 2020-04-10
10-Q 2019-09-30 Filed 2019-11-14
10-Q 2019-06-30 Filed 2019-08-06
10-Q 2019-03-31 Filed 2019-05-13
10-K 2018-12-31 Filed 2019-03-29
10-Q 2018-09-30 Filed 2018-10-31
10-Q 2018-06-30 Filed 2018-08-07
10-Q 2018-03-31 Filed 2018-05-01
10-K 2017-12-31 Filed 2018-03-29
10-Q 2017-09-30 Filed 2017-11-09
10-Q 2017-06-30 Filed 2017-08-11
10-Q 2017-03-31 Filed 2017-05-08
10-K 2016-12-31 Filed 2017-04-17
10-Q 2016-09-30 Filed 2016-11-09
10-Q 2016-06-30 Filed 2016-08-11
10-Q 2016-03-31 Filed 2016-05-10
10-K 2015-12-31 Filed 2016-04-08
10-Q 2015-09-30 Filed 2015-10-30
10-Q 2015-06-30 Filed 2015-08-13
10-Q 2015-03-31 Filed 2015-05-06
10-K 2014-12-31 Filed 2015-04-14
10-Q 2014-09-30 Filed 2014-11-13
10-Q 2014-06-30 Filed 2014-08-12
10-Q 2014-03-31 Filed 2014-05-20
10-K 2013-12-31 Filed 2014-04-18
8-K 2020-04-27 Other Events
8-K 2020-01-29 Sale of Shares, Exhibits
8-K 2019-12-31 Enter Agreement, M&A, Sale of Shares, Other Events, Exhibits
8-K 2019-12-18 Amend Bylaw, Exhibits
8-K 2019-08-27 Sale of Shares

Vaparia Financials

VAPA Metrics, Comps, Filings

Quarterly | Annual

Business

VapAria is a pre-clinical specialty pharmaceutical company. Our operations are focused on the development and commercialization of methods and medicants to address and reduce the harms associated with chronic conditions with novel, vapor-centric, inhalable approaches to pain management, appetite suppression, mood enhancement, smoking and various sleep disorders and doing with patented device methods and patented drug approaches.

Prior to forming VapAria Solutions in 2010, our management had more than 25 years' collective experience in vaporization and vapor delivery of medicants, having been partners in a joint venture with pioneers in the industry and having had undertaken significant work internationally researching and developing products, shepherding them through the patent process and introducing them into the U.S. wholesale and retail supply chain. Our management, through the Chong Corporation, a common control entity that is the licensor of the intellectual property rights described below, has built an extensive and robust portfolio of intellectual property that includes patented and patent-pending methods of vaporization and patented and patent-pending medicants and herbal remedies identified for their effectiveness and suitability to address our target markets.

Our initial goal was to leverage rights we acquired in December 2013 from an affiliate which are described below to develop and successfully launch a product in partnership with well-capitalized and experienced industry participants based on our exclusive license and exclusive options to license patented and patent-pending technologies and formulations designed to significantly improve on current electronic nicotine delivery systems and other consumer products in the marketplace. Since mid-2015 and continuing into the first quarter of 2019, in addition to discussions with third party financing sources, we have engaged in substantive discussions with several U.S. and international companies which have expressed an interest in our licensed technology in pursuit of this strategy.


Valuation ($)

Market Cap, Enterprise Value

Balance Sheet ($)

Assets, Equity

Income Statement ($ Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($ Quarterly)

Ops, Inv, Fin

Comps ($ TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Madison Ventures (MDSV) -0.3 0 748,143,000 0 0 -327,250,000 -289,662,000 97,057,000
Vericity (VERY) 0% 5.7 -1% 806,697,000,000 498,016,000,000 70,671,000,000 0 -11,136,000,000 -11,400,000,000 -64,552,001,000
Anvi Global Holdings (ANVI) 0.3 -162% 139,156,000 1,058,652,000 0 0 -225,126,000 -225,126,000 -69,658,000
Cardinal Ethanol (CARD) 0% -3.1 -5% 137,551,637,000 25,272,954,000 260,669,352,000 35,644,000 -6,598,913,000 5,002,326,000 -15,308,399,000
Monitronics International (MTII) 54% -3.7 -33% 1,457,388,000,000 1,088,795,000,000 428,422,000,000 229,710,000,000 -473,690,000,000 -261,950,000,000 965,324,999,000
ECCO Auto World (ECCO) 100% 0.9 -42% 43,073,000 11,771,000 10,000,000 10,000,000 -18,010,000 -18,010,000 -16,195,000
Protective Life (PL) 0% -0.5 0% 119,751,045,000,000 110,460,110,000,000 5,735,562,000,000 0 383,675,000,000 544,873,000,000 -293,299,002,000
Everflow Eastern Partners (EEPL) 51% -4.2 6% 41,677,704,000 22,380,059,000 6,257,402,000 3,206,894,000 2,357,201,000 2,800,470,000 -11,649,474,000
Reva Medical (RVA) -33% -0.3 154% 10,626,000,000 83,896,000,000 265,000,000 -88,000,000 16,394,000,000 23,305,000,000 -7,094,002,000
Heyu Biological Technology (HEYU) 44% 1.3 -33% 1,079,036,000 1,699,353,000 57,317,000 25,379,000 -357,214,000 -357,214,000 -452,320,000
Fellazo (FLLC) 14.7 -0% 280,000,000 267,199,000 0 0 -172,000 -172,000 -2,520,000
Medixall Group (MDXL) 0% 0.0 -381% 558,749,000 361,594,000 2,253,000 0 -2,129,641,000 -2,129,641,000 -50,709,000
Ultimate Products (ULPC) 0.0 -1,320% 723,000 93,204,000 0 0 -9,540,000 -9,540,000 -2,000
Bankguam (BKGMF) -10.1 1% 1,951,731,000,000 1,790,610,000,000 0 0 12,309,000,000 18,839,000,000 -189,809,002,000
Morgan Stanley Smith Barney Spectrum Select (DWSF) -1.3 14% 32,101,605,000 875,871,000 0 0 4,605,658,000 4,605,658,000 -6,133,405,000
Trine Acquisition (TRNE) -0.2 1% 304,311,637,000 10,706,577,000 0 0 2,053,393,000 2,599,231,000 -588,284,000
Vaparia (VAPA) 0.1 -34% 219,531,000 832,454,000 0 0 -74,606,000 -74,606,000 -7,442,000
Peptide Technologies (PEPT) 0.0 -22% 251,256,000 671,681,000 0 0 -56,398,000 -57,175,000 -1,055,000
Scientific Energy (SCGY) 0.2 -253% 145,768,000 1,980,009,000 0 0 -368,614,000 -365,971,000 -86,026,000
Digital Brand Media & Marketing (DBMM) 10% -1.5 -567% 110,602,000 4,347,324,000 329,232,000 32,002,000 -627,320,000 -536,897,000 820,036,000

Balance Sheet ($)2014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash6,707,000497,00036,018,00012,894,0003,414,0005,915,00010,642,0008,868,0004,459,0004,484,00017,495,00013,260,0003,142,0007,658,0006,538,0005,128,0002,289,0001,477,000457,0002,592,0007,440,000
Accounts Receivable
Inventory
PP&E
Assets00194,441,000185,342,000225,372,000195,485,000183,117,000182,728,000291,703,000280,552,000270,690,000265,263,000277,823,000264,199,000249,461,000249,357,000245,620,000241,001,000232,294,000225,613,000221,460,000220,386,000219,531,000
Accounts Payable2,685,0002,685,00024,564,00036,436,00014,205,00028,054,00071,225,00047,249,00048,974,00046,254,00045,701,00037,068,00031,358,00033,238,00011,012,0008,700,00010,012,0008,562,0006,847,0006,304,0008,775,0009,558,00010,722,000
Long-Term Debt
Liabilities8,685,0008,685,000150,206,000171,190,000140,932,000179,775,000262,963,000327,003,000388,723,000448,247,000497,461,000538,844,000586,107,000619,982,000649,772,000679,476,000707,611,000723,655,000744,076,000763,930,000788,934,000808,151,000832,454,000
Stockholders' Equity-8,685,000-8,685,00044,235,00014,152,00084,440,00015,710,000-79,846,000-144,275,000-97,020,000-167,695,000-226,771,000-273,581,000-308,284,000-355,783,000-400,311,000-430,119,000-461,991,000-482,654,000-511,782,000-538,317,000-567,474,000-587,765,000-612,923,000
Income Statement ($)2014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue0
Cost of Revenue
Gross Profit
R&D25,000,0002,115,00042,201,00041,446,00022,715,00038,253,00034,204,00027,090,00010,784,00017,865,00022,612,00011,180,0005,027,00009,025,000000
SG&A019,306,0002,208,0005,187,00034,489,00020,055,000432,596,0006,159,0007,889,0007,676,000259,625,0007,006,0006,984,0006,993,0007,030,0006,843,0007,020,0007,137,0007,077,0006,936,0006,851,000
Tax00000000000000
Net Income0-17,398,000-24,454,000-39,712,000-98,080,000-110,295,000-491,643,000-53,517,000-70,675,000-59,076,000-299,497,000-34,703,000-23,126,000-44,528,000-29,808,000-31,872,000-8,007,000-29,128,000-29,157,000-20,291,000-25,158,000
Cash Flow ($)2014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-16,210,000-64,479,000-46,124,000-47,480,000-83,499,000-53,273,000-59,774,000-54,409,000-47,975,000-37,989,000-34,235,000-60,118,000-25,484,000-21,120,000-21,410,000-18,839,000-15,520,000-20,365,000-12,152,000
Cash Investing000
Cash Financing10,000,000100,000,00023,000,00038,000,00086,000,00058,000,00058,000,00050,000,00048,000,00051,000,00030,000,00050,000,00030,000,00020,000,00020,000,00016,000,00014,500,00022,500,00017,000,000